159 related articles for article (PubMed ID: 17169692)
1. Microbubble disappearance-time is the appropriate timing for liver-specific imaging after injection of Levovist.
Maruyama H; Matsutani S; Okugawa H; Kobayashi S; Yoshizumi H; Ebara M; Saisho H
Ultrasound Med Biol; 2006 Dec; 32(12):1809-15. PubMed ID: 17169692
[TBL] [Abstract][Full Text] [Related]
2. How to characterize non-hypervascular hepatic nodules on contrast-enhanced computed tomography in chronic liver disease: feasibility of contrast-enhanced ultrasound with a microbubble contrast agent.
Yoshizumi H; Maruyama H; Okugawa H; Kobayashi S; Akiike T; Yoshikawa M; Ebara M; Yokosuka O; Matsutani S; Kondo F; Kamiyama N
J Gastroenterol Hepatol; 2008 Oct; 23(10):1528-34. PubMed ID: 17944882
[TBL] [Abstract][Full Text] [Related]
3. [Characterization of focal liver lesions with contrast-enhanced low MI real time ultrasound and SonoVue].
Hohmann J; Skrok J; Puls R; Albrecht T
Rofo; 2003 Jun; 175(6):835-43. PubMed ID: 12811698
[TBL] [Abstract][Full Text] [Related]
4. Color doppler ultrasound of liver lesions: signal enhancement after intravenous injection of the ultrasound contrast agent Levovist.
Ernst H; Hahn EG; Balzer T; Schlief R; Heyder N
J Clin Ultrasound; 1996 Jan; 24(1):31-5. PubMed ID: 8655665
[TBL] [Abstract][Full Text] [Related]
5. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence.
Quaia E; Calliada F; Bertolotto M; Rossi S; Garioni L; Rosa L; Pozzi-Mucelli R
Radiology; 2004 Aug; 232(2):420-30. PubMed ID: 15286314
[TBL] [Abstract][Full Text] [Related]
6. Corona enhancement in ultrasonographical post-vascular phase images with microbubble contrast agent: a novel specific sign for hepatocellular carcinomas.
Yamamoto K; Nakanishi S; Fuke H; Hashimoto A; Shimizu A; Hamataki T; Shiraki K
Oncol Rep; 2006 Apr; 15(4):785-90. PubMed ID: 16525659
[TBL] [Abstract][Full Text] [Related]
7. Small hepatic nodules (< or =2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography.
Wang JH; Lu SN; Hung CH; Chen TY; Chen CH; Changchien CS; Lee CM
Liver Int; 2006 Oct; 26(8):928-34. PubMed ID: 16953832
[TBL] [Abstract][Full Text] [Related]
8. Analysis of different contrast enhancement patterns after microbubble-based contrast agent injection in liver hemangiomas with atypical appearance on baseline scan.
Quaia E; Bartolotta TV; Midiri M; Cernic S; Belgrano M; Cova M
Abdom Imaging; 2006; 31(1):59-64. PubMed ID: 16333704
[TBL] [Abstract][Full Text] [Related]
9. Focal hepatic lesions: contrast-enhancement patterns at pulse-inversion harmonic US using a microbubble contrast agent.
Kim EA; Yoon KH; Lee YH; Kim HW; Juhng SK; Won JJ
Korean J Radiol; 2003; 4(4):224-33. PubMed ID: 14726639
[TBL] [Abstract][Full Text] [Related]
10. [Contrast enhanced power Doppler sonography: comparison of various administration forms of the ultrasound contrast agent Levovist].
Kratzer W; Kächele V; Merkle E; Mason RA; Büchner M; von Tirpitz C; Pfeiffer M
Rofo; 2000 May; 172(5):443-8. PubMed ID: 10874971
[TBL] [Abstract][Full Text] [Related]
11. Differential patterns of contrast enhancement in different focal liver lesions after injection of the microbubble US contrast agent SonoVue.
Quaia E; Degobbis F; Tona G; Mosconi E; Bertolotto M; Pozzi Mucelli R
Radiol Med; 2004 Mar; 107(3):155-65. PubMed ID: 15031681
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of hypervascular hepatocellular carcinoma in cirrhotic liver by means of helical CT: comparison of different contrast medium concentrations within the same patient.
Sultana S; Morishita S; Awai K; Kawanaka K; Ohyama Y; Nakayama Y; Imuta M; Arakawa A; Yamashita Y
Radiat Med; 2003; 21(6):239-45. PubMed ID: 14743896
[TBL] [Abstract][Full Text] [Related]
13. Assessment of hepatic fibrosis by analysis of the dynamic behaviour of microbubbles during contrast ultrasonography.
Ishibashi H; Maruyama H; Takahashi M; Fujiwara K; Imazeki F; Yokosuka O
Liver Int; 2010 Oct; 30(9):1355-63. PubMed ID: 20704652
[TBL] [Abstract][Full Text] [Related]
14. Contrast-enhanced US with Levovist for the diagnosis of hepatic hemangioma: time-related changes of enhancement appearance and the hemodynamic background.
Kobayashi S; Maruyama H; Okugawa H; Yoshizumi H; Matsutani S; Ebara M; Yokosuka O
Hepatogastroenterology; 2008; 55(85):1222-8. PubMed ID: 18795661
[TBL] [Abstract][Full Text] [Related]
15. Characterization of focal hepatic lesions in cirrhotic patients by Pulse Inversion Harmonic Imaging US contrast specific technique with Levovist.
Quaia E; Forgács B; Calderan L; Bertolotto M; Pozzi Mucelli R
Radiol Med; 2002 Oct; 104(4):285-94. PubMed ID: 12569309
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic and morphologic changes of peripheral hepatic vasculature in cirrhotic liver disease: a preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonography.
Zheng RQ; Zhang B; Kudo M; Sakaguchi Y
World J Gastroenterol; 2005 Oct; 11(40):6348-53. PubMed ID: 16419164
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy.
Tarantino L; Francica G; Sordelli I; Esposito F; Giorgio A; Sorrentino P; de Stefano G; Di Sarno A; Ferraioli G; Sperlongano P
Abdom Imaging; 2006; 31(5):537-44. PubMed ID: 16865315
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound contrast agent Levovist in colour Doppler sonography of hepatocellular carcinoma in Chinese patients.
Khong PL; Chau MT; Fan ST; Leong LL
Australas Radiol; 1999 May; 43(2):156-9. PubMed ID: 10901894
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of digital subtraction imaging with Levovist in the diagnosis of focal hepatic tumors.
Yamamoto K; Shiraki K; Nakanishi S; Deguchi M; Sugimoto K; Sakai T; Ohmori S; Murata K; Fuke H; Hashimoto A; Shimizu A; Okuda Y; Nakano T
Int J Oncol; 2003 Feb; 22(2):353-8. PubMed ID: 12527934
[TBL] [Abstract][Full Text] [Related]
20. Signal intensity of the liver parenchyma in microbubble contrast agent in the late liver phase reflects advanced fibrosis of the liver.
Kaneko T; Teshigawara O; Sugimoto H; Hirota M; Inoue S; Takeda S; Nakao A
Liver Int; 2005 Apr; 25(2):288-93. PubMed ID: 15780052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
